Boston Scientific starts brain aneurysm trial
Boston Scientific Corp. said today it has enrolled its first patient in a clinical trial designed to evaluate an endovascular treatment of brain aneurysms.
The Natick company develops, manufactures, and markets such medical devises as stents, which can be used to keep open arteries that have been unclogged during medical procedures.
In the brain aneurysm trial, patients in the study will be randomized to receive either Matrix2 detachable coils or GDC detachable coils, which are the first bare platinum detachable coil cleared for aneurysm treatment, the company said.
Matrix2 coils are covered with an acid bio-polymer shown to improve durability in preclinical studies, the company said.
"Not only is this trial important in its own right, but it further demonstrates that multi-disciplinary aneurysm trials can and will help define the future of aneurysm treatment," Cameron McDougall, co-principal investigator of the trial, said in a statement.
(By Chris Reidy, Globe staff)